Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes.
Saved in:
| Title: | Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes. |
|---|---|
| Authors: | Graham R; Breast Immunology Group, School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom., Gazinska P; Breast Cancer Now Research Unit, King's College London, Guy's Hospital, London, United Kingdom.; Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom.; Biobank Research Group, Lukasiewicz Research Network - PORT Polish Center for Technology Development, Wroclaw, Poland., Zhang B; Systems Immunity University Research Institute and Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom., Khiabany A; Breast Immunology Group, School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom., Sinha S; Breast Immunology Group, School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom., Alaguthurai T; Breast Immunology Group, School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom.; Breast Cancer Now Research Unit, King's College London, Guy's Hospital, London, United Kingdom., Flores-Borja F; Richard Dimbleby Laboratory of Cancer Research School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom., Vicencio J; UCL Cancer Institute, Paul O'Gorman Building, University College London, London, United Kingdom., Beuron F; Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom., Roxanis I; Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom., Matkowski R; Breast Unit, Lower Silesian Oncology, Pulmunology and Hematology Center, Wroclaw, Poland.; Department of Oncology, Wroclaw Medical University, Wroclaw, Poland., Liam-Or R; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Tutt A; Breast Cancer Now Research Unit, King's College London, Guy's Hospital, London, United Kingdom.; Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research, London, United Kingdom., Ng T; Breast Cancer Now Research Unit, King's College London, Guy's Hospital, London, United Kingdom.; Richard Dimbleby Laboratory of Cancer Research School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.; UCL Cancer Institute, Paul O'Gorman Building, University College London, London, United Kingdom., Al-Jamal KT; Institute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom., Zhou Y; Systems Immunity University Research Institute and Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom., Irshad S; Breast Immunology Group, School of Cancer & Pharmaceutical Sciences, King's College London, London, United Kingdom.; Breast Cancer Now Research Unit, King's College London, Guy's Hospital, London, United Kingdom.; Medical Oncology, Guy's & St Thomas' NHS Trust, London, United Kingdom. |
| Source: | Frontiers in immunology [Front Immunol] 2023 Jun 22; Vol. 14, pp. 1204224. Date of Electronic Publication: 2023 Jun 22 (Print Publication: 2023). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
